Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Comprar returned no results
Showing 16 to 30 of 555 results for compare

  1. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

    Technology appraisal guidance
    Published
    6 February 2018
    View recommendations

    Sections for TA504

  2. PneuX to prevent ventilator-associated pneumonia (HTG543)

    Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.

    HealthTech guidance
    Published
    8 April 2020
    View recommendations

    Sections for HTG543

  3. Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. [new 2013]

    Impact of risk-reducing surgery:- Further research is recommended to compare psychosocial and clinical outcomes in women who choose and...

    Research recommendation
    Published
    9 June 2015

  4. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA379

  5. Oral health promotion: general dental practice (NG30)

    This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.

    NICE guideline
    Published
    15 December 2015
    View recommendations

    Sections for NG30

  6. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia...

    Research recommendation
    Published
    14 November 2018

  7. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA116

  8. Joint replacement (primary): hip, knee and shoulder (NG157)

    This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.

    NICE guideline
    Published
    4 June 2020
    View recommendations

    Sections for NG157

  9. Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase inhibitors and tamoxifen for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer. [new 2013]

    incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase...

    Research recommendation
    Published
    9 June 2015

  10. Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

    Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA814

  11. Eating disorders: recognition and treatment (NG69)

    This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.

    NICE guideline
    Last updated
    16 December 2020
    View recommendations

    Sections for NG69

  12. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA905

  13. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

    Evidence summary
    Published
    10 August 2021

  14. Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the...

    Research recommendation
    Published
    13 August 2021

  15. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512